CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S PRODUCTION WORKSHOPS FOR CEPHALOSPORIN PRODUCTS "CEFOTAXIME SODIUM FOR INJECTION" AND "CEFIXIME TABLET" PASSED ONSITE INSPECTION BY THE U.S. FDA

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries (the "**Group**")) announces that the Group has received the report from the U.S. Food and Drug Administration ("**U.S. FDA**") confirming that the Group's production workshops for cephalosporin products "Cefotaxime Sodium for Injection" and "Cefixime Tablet" have passed the U.S. FDA onsite inspection with zero-fault.

As a third generation semi-synthetic cephalosporin, cefotaxime sodium has a wide anti-bacterial spectrum and high anti-bacteria activities against Gram-positive and negative bacteria. It has a high bacteria killing efficacy especially for Gram-negative bacteria. In clinical use, it is mainly indicated for infections caused by different susceptible bacteria, such as respiratory infection, abdominal infection, meningitis, gonorrhea, urinary tract infection, sepsis and etc. Cefixime Tablet is a wide-spectrum anti-bacterial drug. In clinical use, it is mainly indicated for the acute exacerbation of chronic bronchitis, acute bronchitis complicated by bacterial infection, bronchodilation complicated infection, pneumonia, pyelonephritis, cystitis, urethritis, cholecystitis, cholangitis, otitis media and etc.

It has been only about one year and a half from the submission of the Abbreviated New Drug Application for Cefotaxime Sodium for Injection to the U.S. FDA by the Group in September 2012 to the passing of the onsite inspection of the production workshops by the U.S. FDA in April 2014, representing the first case in the domestic pharmaceutical industry in terms of the processing time. Moreover, Cefotaxime Sodium for Injection is a sterile preparation requiring extremely stringent standards on the production environment. The zero-fault passing of the onsite inspection of the production workshop by the U.S. FDA reflects the attainment of international advanced standards by the Group's quality management system.

Symbolising a breakthrough advancement for the Group's cephalosporin injection and oral products expanding into the international market, this passing of the onsite inspection by the U.S. FDA lays a solid foundation for the entry of the Group's cephalosporin products into the United States, Australia, New Zealand, South Africa, Turkey and other international markets.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 17 November 2014

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo and Mr. WANG Jinxu as executive Directors; Mr. LEE Ka Sze, Carmelo as non-executive Director and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Shilin as independent non-executive Directors.